tiprankstipranks
Trending News
More News >
Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Hong Kong Market

Clover Biopharmaceuticals Ltd. (2197) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Clover Biopharmaceuticals Ltd.

(2197)

Rating:54Neutral
Price Target:
HK$0.50
▲(66.67%Upside)
Clover Biopharmaceuticals' financial situation is the most significant factor, heavily weighing down the overall score due to persistent losses, high leverage, and negative cash flows. While technical analysis provides some positive signs, suggesting short-term bullish momentum, valuation concerns remain due to ongoing losses. The absence of positive earnings call data and corporate events further limits the score.

Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)

Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company DescriptionClover Biopharmaceuticals Ltd. (2197) is a global clinical-stage biotechnology company focused on discovering, developing, and commercializing transformative biologic therapies. The company primarily operates in the biopharmaceutical sector, with a core emphasis on developing vaccines and biologic therapies for infectious diseases and cancer. Clover Biopharmaceuticals leverages its proprietary Trimer-Tag technology platform to create innovative treatments aimed at addressing significant unmet medical needs worldwide.
How the Company Makes MoneyClover Biopharmaceuticals makes money through the development and commercialization of its biologic therapies and vaccines. The company's primary revenue streams include partnerships and collaborations with other pharmaceutical companies, government contracts, and potential sales of its proprietary products upon regulatory approval. Clover's significant partnerships with global health organizations and pharmaceutical firms help fund its research and development efforts while providing opportunities for co-development and commercialization. Additionally, the company may receive milestone payments and royalties from its collaborations, contributing to its earnings as its products progress through clinical trials and towards market approval.

Clover Biopharmaceuticals Ltd. Financial Statement Overview

Summary
Clover Biopharmaceuticals faces significant financial challenges, including persistent losses, negative equity, and negative cash flows. High financial leverage and an inability to generate positive cash flow from operations highlight the company's precarious financial position, which could affect its future operations and growth prospects.
Income Statement
20
Very Negative
Clover Biopharmaceuticals has consistently reported negative net income, with significant losses in gross profit and EBIT. The revenue growth has been negligible, indicating challenges in generating sales. The negative margins reflect difficulty in controlling costs relative to revenue.
Balance Sheet
15
Very Negative
The company's balance sheet is highly leveraged, with negative stockholders' equity indicating insolvency risks. The debt-to-equity ratio is not meaningful due to negative equity. Asset base is shrinking, and the negative equity ratio suggests financial instability.
Cash Flow
25
Negative
Operating cash flows have been negative, showing challenges in generating cash from operations. The cash position has decreased over time, and free cash flow is consistently negative, which may hinder future growth and investment capabilities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue38.42M39.26M0.000.000.00
Gross Profit-672.94M24.24M-475.64M-66.27M0.00
EBITDA-916.54M-45.07M-2.39B-2.23B-335.04M
Net Income-903.43M-138.54M-2.45B-6.02B-915.87M
Balance Sheet
Total Assets812.74M2.10B4.69B5.35B1.19B
Cash, Cash Equivalents and Short-Term Investments427.53M752.97M1.64B2.87B806.51M
Total Debt89.64M334.45M354.37M67.92M22.32M
Total Liabilities2.45B2.83B5.36B4.13B2.17B
Stockholders Equity-1.64B-732.83M-668.14M1.22B-982.74M
Cash Flow
Free Cash Flow-290.11M-737.05M-1.80B-998.07M363.13M
Operating Cash Flow-288.49M-727.88M-1.69B-917.75M476.93M
Investing Cash Flow3.17M-6.16M-37.51M112.12M-394.12M
Financing Cash Flow-51.50M-142.41M483.14M3.06B316.85M

Clover Biopharmaceuticals Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.30
Price Trends
50DMA
0.24
Positive
100DMA
0.26
Positive
200DMA
0.27
Positive
Market Momentum
MACD
0.02
Negative
RSI
66.18
Neutral
STOCH
75.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.24, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 66.18 is Neutral, neither overbought nor oversold. The STOCH value of 75.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2197.

Clover Biopharmaceuticals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$15.71B5.67-7.43%4.09%11.60%-21.06%
54
Neutral
HK$389.12M
-1.73%-689.53%
52
Neutral
HK$659.39M-266.90%31.23%
47
Neutral
HK$640.84M-32.59%-79.65%37.50%
46
Neutral
HK$3.81B-69.97%3.30%
45
Neutral
HK$7.01B289.312.28%-57.55%-87.49%
36
Underperform
HK$660.43M-41.20%85.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2197
Clover Biopharmaceuticals Ltd.
0.30
0.00
0.00%
HK:6628
Transcenta Holding Limited
1.50
0.02
1.35%
HK:2257
Sirnaomics Ltd.
6.27
2.22
54.81%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
7.96
-0.19
-2.33%
HK:2142
HBM Holdings Ltd.
8.39
7.09
545.38%
HK:9939
Kintor Pharmaceutical Ltd
1.50
0.50
50.00%

Clover Biopharmaceuticals Ltd. Corporate Events

Clover Biopharmaceuticals Announces Board and Committee Changes
Jul 2, 2025

Clover Biopharmaceuticals Ltd. announced changes to its board of directors and committee memberships, effective July 1, 2025. Dr. Donna Marie Ambrosino and Mr. Xiang Liao have been appointed as members of the Nomination Committee, reflecting the company’s ongoing efforts to strengthen its governance structure.

Clover Biopharmaceuticals Strengthens Governance with New Nomination Committee
Jul 2, 2025

Clover Biopharmaceuticals Ltd. has established a Nomination Committee to oversee director appointments, ensuring diversity and independence within its board. This move is part of the company’s governance strategy to enhance operational efficiency and maintain transparency, potentially strengthening its industry position and stakeholder confidence.

Clover Biopharmaceuticals Announces Unanimous AGM Results and Director Retirement
Jun 19, 2025

Clover Biopharmaceuticals Ltd. announced the results of its Annual General Meeting held on June 19, 2025, where all proposed resolutions were passed unanimously. The meeting also marked the retirement of a non-executive director, and the re-election of other directors, along with the appointment of a new auditor, highlighting the company’s stable governance and strategic planning.

Clover Biopharmaceuticals Launches Phase I Trial for New Respiratory Vaccines
Jun 17, 2025

Clover Biopharmaceuticals Ltd. has initiated a Phase I clinical trial for its new respiratory combination vaccine candidates, SCB-1022 and SCB-1033, which target RSV, hMPV, and PIV3. This trial follows promising results from a previous study comparing Clover’s RSV PreF vaccine candidate to GSK’s AREXVY, indicating a strong immunogenicity and tolerability profile. The ongoing trial will enroll up to 192 older adults to assess the safety, reactogenicity, and immunogenicity of these new vaccine candidates, potentially strengthening Clover’s position in the vaccine market.

Clover Biopharmaceuticals Ends Distribution Agreement with Adimmune
Jun 15, 2025

Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.

Clover Biopharmaceuticals Faces Arbitration Over $224 Million Claim
Jun 8, 2025

Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.

Clover Biopharmaceuticals Announces 2025 Annual General Meeting Agenda
May 21, 2025

Clover Biopharmaceuticals Ltd. has announced its upcoming annual general meeting scheduled for June 19, 2025, in Chengdu, China. Key agenda items include the adoption of financial statements for 2024, re-election of directors, and the appointment of auditors. Additionally, the meeting will address resolutions to authorize the board to manage share capital, which may impact the company’s future financial strategies and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 01, 2025